Enterprise Value

805.1M

Cash

322.2M

Avg Qtr Burn

-41.73M

Short % of Float

28.22%

Insider Ownership

9.07%

Institutional Own.

90.61%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vonoprazan (Potassium competitive acid blocker) Details
Intestinal infection, Esophagitis, Gastroesophageal reflux disease

Approved

Quarterly sales

Approved

Quarterly sales

VOQUEZNA® (vonoprazan) Details
Gastroesophageal reflux disease

Big Mover™

Susp. Mover™

PDUFA

Approval decision

VOQUEZNA® (vonoprazan) Details
Gastroesophageal reflux disease

Phase 3

Initiation

VOQUEZNA® (vonoprazan) Details
Eosinophilic Esophagitis

Phase 2

Initiation